MyChesCo on MSN

Prelude Therapeutics reports 2025 results and advances oncology pipeline

WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) reported its financial results for the year ended December 31, 2025 ...
Medscape

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or ...

Akeso shares rise as cancer drug candidate enters clinical trials

Investing.com-- Shares of Hong Kong-listed biotech firm Akeso (HK:9926) rose on Monday after the company said a new cancer drug candidate had received regulatory clearance to begin clinical testing, ...

AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment

AstraZeneca PLC (NYSE: AZN) is one of Goldman Sachs top healthcare stocks. On March 9, AstraZeneca PLC (NYSE:AZN) and Daiichi ...
MyChesCo on MSN

FDA moves to cut costs for biosimilar drug development

WASHINGTON, D.C. — The U.S. Food and Drug Administration announced new draft guidance aimed at reducing the cost and complexity of developing biosimilar medicines, a move the agency says could ...